Bipolar disorder (BD) is a leading cause of global disability. Its biological basis is unknown, and its treatment unsatisfactory. Here, we review two recent areas of progress. First, the discovery of risk genes and their implications, with a focus on voltage-gated calcium channels as part of the disease process and as a drug target. Second, facilitated by new technologies, it is increasingly apparent that the bipolar phenotype is more complex and nuanced than simply one of recurring manic and depressive episodes. One such feature is persistent mood instability, and efforts are underway to understand its mechanisms and its therapeutic potential. [ 3 1 7 _ T D $ D I F F ] BD illustrates how psychiatry is being transformed by contemporary neuroscience, genomics, and digital approaches.
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Bipolar Disorder and the New Psychiatry
Psychiatry still relies largely on 19th-Century diagnostic categories. These are based on clusters of symptoms rather than biological markers, and are treated with drugs discovered serendipitously several decades ago. BD typifies this unsatisfactory state of affairs. Although its name has changed [it was formerly known as manic depression (see Glossary)], its cardinal features, and how it is assessed and treated (Box 1) have barely altered. An important reason for this stagnation has been the lack of any real traction on its causes and underlying biology, beyond its well-established high heritability [1] . Although there is evidence for altered structural and functional brain connectivity [2] [3] [4] , and changes in markers of oxidative stress [5], mitochondrial function [6] , inflammation [7], circadian rhythms [8], and dopamine [9], it remains difficult to integrate these diverse findings, and to disentangle causative changes from those that are secondary to the disorder and its treatment.
The situation is belatedly improving. While optimism must be tempered by appreciation of the many complexities, there are realistic prospects for a transformation in our understanding of BD and how it is diagnosed and treated. Here, we highlight two areas of current interest: the discovery of the first BD risk genes and their implications, and the application of novel technologies with the potential to refine, or redefine, the BD phenotype. These developments exemplify how genomics, neuroscience, and digital technologies are heralding a new era for psychiatry. For broader reviews of BD, see [10, 11] .
The Genomics of Bipolar Disorder
A child of an affected parent has about a tenfold increased risk of developing BD, and twin studies estimate a heritability of 0.7-0.8 [1] . There is no evidence for Mendelian inheritance or for genes of major effect. Instead, as with most psychiatric disorders, there are multiple susceptibility loci, each of small effect, which genome-wide association studies (GWAS) are beginning to identify. Several GWAS, and meta-analyses thereof, have been carried out since 2007; Table 1 lists the loci and implicated genes that have emerged to date. The combined Trends BD is highly heritable and mostly attributable to common variants of small effect. Several risk genes and gene networks have been identified.
Calcium signalling is prominent among the genetic risk pathways, and currently appears to have the greatest therapeutic traction.
Digital technologies and sophisticated mathematical and computational analyses are being used to quantify and understand BD. Stem cells are becoming an integral part of the approaches to understanding BD and its pharmacotherapy.
New [ 3 1 9 _ T D $ D I F F ] experimental medicine models are being applied to identify and rapidly test potential mood-stabilising treatments. 
